Pharmacotherapy in Systemic Rheumatic Diseases

Borham, Layla E.; Hafiz, Waleed

doi:10.1007/978-981-15-8323-0_4

Cited by 2 publications

(3 citation statements)

References 34 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab (RTX) is a chimeric monoclonal antibody that binds to CD20 antigen and leads to B-cell inhibition. It has numerous therapeutic indications, with rheumatoid arthritis, small vessel vasculitis, non-Hodgkin lymphoma and leukemia being the most common ones [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…These include conventional synthetic DMARDs such as methotrexate, azathioprine, mycophenolate, and cyclophosphamide. Biological DMARDs such as adalimumab and RTX (via either intravenous or intraorbital route) are considered after the failure of the conventional synthetic DMARDs [ 4 ]. Here in, we report a case of IOI treated with RTX monotherapy without the use of conventional synthetic therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Idiopathic Orbital Inflammation Treated With Rituximab Monotherapy

Bawazeer¹,

Rahali²,

Alsharif³

et al. 2023

Cureus

View full text Add to dashboard Cite

Idiopathic orbital inflammation is a benign condition that affects the orbit and the extra-orbital structures. It presents as ocular pain, peri-orbital swelling, proptosis, and restricted ocular movements. This condition is diagnosed based on clinical features that are then confirmed by radiological and histopathological findings. Corticosteroids are the initial therapy of choice. Disease-modifying antirheumatic drugs are added in steroid non-responsive patients. Rituximab is now becoming increasingly used as a third-line therapy for this disease. We report a case of idiopathic orbital inflammation treated with rituximab monotherapy without the use of corticosteroids or disease-modifying antirheumatic drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Idiopathic Orbital Inflammation Treated With Rituximab Monotherapy

Bawazeer¹,

Rahali²,

Alsharif³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…They have both anti-inflammatory and immunomodulatory effects, thus slowing the disease process and preventing joint deformity. Among these medications is a medication called tocilizumab [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Tocilizumab-Induced Dermatosis in a Patient With Rheumatoid Arthritis

Babkoor¹,

Alshuqayfi²,

Alshegaifi³

et al. 2022

Cureus

View full text Add to dashboard Cite

Rheumatoid arthritis is a chronic systemic autoimmune disease that results in symmetrical inflammatory polyarthritis with extra-articular involvement, including skin manifestations. It targets the lining of the synovial membranes and is treated with disease-modifying antirheumatic drugs. If left untreated, it leads to increased morbidity, mortality, and socioeconomic burdens. Tocilizumab is a humanized monoclonal antibody that binds to interleukin-6 receptors and is used to treat rheumatoid arthritis in patients with inadequate response to conventional synthetic therapy. This medication can cause adverse dermatologic events, such as urticaria, pruritus, and mild maculopapular rash. In this case, we report a 39-year-old woman with rheumatoid arthritis who developed tocilizumab-induced dermatosis.

show abstract

Pharmacotherapy in Systemic Rheumatic Diseases

Abstract: By the end of this chapter, you should be able to:

Cited by 2 publications

References 34 publications

Idiopathic Orbital Inflammation Treated With Rituximab Monotherapy

Idiopathic Orbital Inflammation Treated With Rituximab Monotherapy

Tocilizumab-Induced Dermatosis in a Patient With Rheumatoid Arthritis

Contact Info

Product

Resources

About